BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
VANCOUVER, British Columbia, April 26, 2018 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Main, President & CEO, will provide a corporate update at the upcoming 2018 Bloom Burton & Co. Healthcare Conference in Toronto on Thursday, May 3rd 2018.
Aquinox Presentation Details
Date: Thursday, May 3rd 2018
Time: 7:30 am Pacific Time / 10:30 am Eastern Time
Location: Toronto, ON – Sheraton Centre Hotel Toronto
A live audio webcast and archive of the event will be available at:
http://wsw.com/webcast/bloomburton3/aqxp/
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a condition for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit http://www.aqxpharma.com/.
Investor Contact Info:
Brendan Payne
Associate Director, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
